Capricor Therapeutics rises on meeting with US FDA for muscle disorder therapy

Shares of therapy developer Capricor Therapeutics CAPR.O up 3.22% at $8.33 premarket

Co says meeting with U.S. FDA has been scheduled to discuss regulatory path of its cell therapy for treatment of cardiomyopathy associated with Duchenne muscular dystrophy, which is type of muscle disorder

To accommodate this meeting, co has rescheduled release of its Q2 results to August 11 from August 12

FDA in July declined to approved Deramiocel, saying the therapy does not meet efficacy requirements and asked for more data

Up to last close, stock down 41.5% YTD